GERN
GeronANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
RYTELO revenue growth, reiterated 2026 guidance, potential second-half data and a European commercial strategy could support a rerating from the $1.44 anchor price.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Clinical, regulatory, manufacturing and post-marketing execution risks remain relevant to RYTELO and the IMpactMF program [#IR-2026-01-12].
Momentum
87
Value
41
Sentiment
81
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.65 · Bull $2.75 · Bear $0.80
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $3.40
Why
Momentum87 · Δ7d -
Value41 · Δ7d -0.1
Sentiment81 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
87
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
81
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 87.1 / Value 41.1 / Sentiment 81.2
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$923.79M
Beta
0.62
Shares Out
641.52M
P/E (TTM) · Derived
-11.5
P/S (TTM)
4.59
P/FCF (TTM) · Derived
-7.23
Rev YoY
+30.9%
EPS YoY
-81.9%
Gross Margin
+97.0%
Op Margin
-35.3%
Net Debt
-$108.23M
Current Ratio
6.78
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology